The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
3.
BINDING AGENTS HAVING ALTERED FC-MEDIATED EFFECTOR FUNCTIONS
The present invention relates to CH3 domain-containing binding agents, such as antibodies, that have altered Fc-mediated effector functions resulting from one or more amino acid modifications in the Fc domain. The invention further relates to polynucleotides encoding such binding agents, cells capable of producing such binding agents and the use of the binding agents of the invention for the treatment of diseases.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
4.
METHOD FOR CO-EXPRESSION OF A PLURALITY OF ANTIBODIES
The present invention relates to kits and compositions comprising polynucleotides encoding monomer polypeptides, wherein each monomer is capable of forming homodimers, but where heterodimer formation with other monomers is disfavoured thus enabling the simultaneous production of a plurality of different homodimers.
As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the poly-peptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
9.
ANTI-DR5 FAMILY ANTIBODIES, BISPECIFIC OR MULTIVALENT ANTI-DR5 FAMILY ANTIBODIES AND METHODS OF USE THEREOF
Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
10.
A COMPOSITION OF ANTI-DR5 ANTIBODIES AND AN IMMUNOMODULATORY IMIDE DRUG FOR USE IN TREATING MULTIPLE MYELOMA
The present invention relates to the treatment of multiple myeloma using a combination of two antibody molecules that bind to human DR5 antigen and an immunomodulatory imide dmg. The present invention further relates to treatment of relapsed and/or refectory multiple myeloma.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention relates to methods for the quantification of glycoproteins in a sample, comprising quantifying said glycoproteins by comparison with an internal standard, wherein said internal standard comprises variant forms of said glycoproteins, wherein said variant forms contain only core Asn-linked GlcNAc moieties.
The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention relates to combination therapy involving two or more antibodies, wherein the Fc regions of the two antibodies have been modified such that hetero-oligomerization between the antibodies is strongly favored over self-oligomerization when antibodies are bound to their corresponding target antigens and such that hetero-oligomerization-independent effector functions of one or both antibodies are eliminated or strongly reduced. The invention also relates to antibodies, compositions, and kits suitable for use in the combination therapy of the invention.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
15.
ANTI-DEATH RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of infectious diseases using these compositions
The present invention relates to a combination of two antibody molecules that bind to human DR5 antigen and their use in treating cancer. In particular, the present invention relates to dosage regimens for such anti-DR5 antibodies comprising administering to subject weekly dosages followed by biweekly dosages, or one or two priming dosage(s) followed by biweekly dosages.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 35/02 - Antineoplastic agents specific for leukemia
18.
A COMBINATION OF ANTI-DR5 ANTIBODIES AND AN IMMUNOMODULATORY IMIDE DRUG FOR USE IN TREATING MULTIPLE MYELOMA
The present invention relates to the treatment of multiple myeloma using a combination of two antibody molecules that bind to human DR5 antigen and an immunomodulatory imide drug. The present invention further relates to treatment of relapsed and/or refectory multiple myeloma.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 15/62 - DNA sequences coding for fusion proteins
The invention relates to methods for the quantification of glycoproteins in a sample, comprising quantifying said glycoproteins by comparison with an internal standard, wherein said internal standard comprises variant forms of said glycoproteins, wherein said variant forms contain only core Asn-linked GlcNAc moieties.
Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
The invention relates to combination therapy involving two or more antibodies, wherein the Fc regions of the two antibodies have been modified such that hetero-oligomerization between the antibodies is strongly favored over self-oligomerization when antibodies are bound to their corresponding target antigens and such that hetero-oligomerization-independent effector functions of one or both antibodies are eliminated or strongly reduced. The invention also relates to antibodies, compositions, and kits suitable for use in the combination therapy of the invention.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
The present invention relates to combination therapy involving two or more Fc region-containing antigen-binding polypeptides, such as antibodies, wherein the polypeptides have been modified such that hetero-oligomerization between the polypeptides is strongly favored over homo-oligomerization when the polypeptides are bound to their corresponding target antigens. The invention also relates to polypeptides, compositions, kits and devices suitable for use in the combination therapy of the invention.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a combination of two antibody molecules that bind to human DR5 antigen and their use in treating cancer. In particular, the present invention relates to dosage regimens for such anti-DR5 antibodies comprising administering to subject weekly dosages followed by biweekly dosages, or one or two priming dosage(s) followed by biweekly dosages.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Chemical, biochemical, biological, and biotechnological
preparations, especially antibodies, and bi- and
multispecific antibodies as well as fragments, including
monovalent antibodies, derivatives or conjugates of any of
these for in vitro and in vivo scientific and industrial
research and development with regard to diseases; active
chemical ingredients for use in the manufacture of
pharmaceuticals. Pharmaceutical and veterinary preparations, including
pharmaceutical preparations based on antibodies, and bi- and
multispecific antibodies as well as fragments, including
monovalent antibodies, derivatives or conjugates of any of
these for use with regard to diseases. Medical scientific and biological research, especially
research into antibodies and bi- and multispecific
antibodies or fragments, including monovalent antibodies,
derivatives or conjugates of any of these and development of
pharmaceutical products based on antibodies and bi- and
multispecific antibodies or fragments, including monovalent
antibodies, derivatives or conjugates of any of these;
chemical analysis; computer programming, namely programming
of computers for the collection and processing of medical
data in medical scientific research, development and
therapy, including scientific research, development and
therapy with antibodies and bi- and multispecific antibodies
or fragments, including monovalent antibodies, derivatives
or conjugates of any of these. Patent exploitation and licensing of intellectual property
in the field of medicine.
The present invention relates to combination therapy involving two or more Fc region-containing antigen-binding polypeptides, such as antibodies, wherein the polypeptides have been modified such that hetero-oligomerization between the polypeptides is strongly favored over homo-oligomerization when the polypeptides are bound to their corresponding target antigens. The invention also relates to polypeptides, compositions, kits and devices suitable for use in the combination therapy of the invention.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
[ Chemical, biochemical, biological, and biotechnological, preparations, namely, antibodies, bi- and multispecific antibodies as well as antibody fragments, monovalent antibodies, and derivatives of conjugates of any of these for in vitro and in vivo scientific and industrial research and development with regard to diseases; active chemical ingredients for use in the manufacture of pharmaceuticals ] [ Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations based on antibodies, and bi- and multispecific antibodies as well as antibody fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases ] Medical scientific and biological research, namely research into antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these and development of pharmaceutical products based on antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these [ ; chemical analysis; computer programming, namely programming of computers for the collection and processing of medical data in medical scientific research, development and therapy, including scientific research, development and therapy with antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these ] [ Legal services in the field of patent exploitation; licensing of intellectual property in the field of medicine ]
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
(1) Chemical, biochemical, biological, and biotechnological preparations, especially antibodies, and bi- and multispecific antibodies as well as fragments, namely monovalent antibodies, derivatives and conjugates of any of these for in vitro and in vivo scientific industrial research and development with regard to diseases; active chemical ingredients for use in the manufacture of pharmaceuticals.
(2) Pharmaceutical and veterinary preparations, namely pharmaceutical preparations based on antibodies, and bi- and multispecific antibodies as well as fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases. (1) Medical, scientific and biological research, especially research into antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these and development of pharmaceutical products based on antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these; chemical analysis; computer programming, namely programming of computers for the collection and processing of medical data in medical scientific research, development and therapy, including scientific research, development and therapy with antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these.
(2) Patent exploitation and licensing of intellectual property in the field of medicine.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Chemical, biochemical, biological, and biotechnological
preparations, especially antibodies, and bi- and
multispecific antibodies as well as fragments, including
monovalent antibodies, derivatives or conjugates of any of
these for in vitro and in vivo scientific and industrial
research and development with regard to diseases; active
chemical ingredients for use in the manufacture of
pharmaceuticals. Pharmaceutical and veterinary preparations, including
pharmaceutical preparations based on antibodies, and bi- and
multispecific antibodies as well as fragments, including
monovalent antibodies, derivatives or conjugates of any of
these for use with regard to diseases. Medical, scientific and biological research, especially
research into antibodies and bi- and multispecific
antibodies or fragments, including monovalent antibodies,
derivatives or conjugates of any of these and development of
pharmaceutical products based on antibodies and bi- and
multispecific antibodies or fragments, including monovalent
antibodies, derivatives or conjugates of any of these;
chemical analysis; computer programming, namely programming
of computers for the collection and processing of medical
data in medical scientific research, development and
therapy, including scientific research, development and
therapy with antibodies and bi- and multispecific antibodies
or fragments, including monovalent antibodies, derivatives
or conjugates of any of these. Patent exploitation and licensing of intellectual property
in the field of medicine.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Chemical, biochemical, biological, and biotechnological
preparations, especially antibodies, and bi- and
multispecific antibodies as well as fragments, including
monovalent antibodies, derivatives or conjugates of any of
these for in vitro and in vivo scientific and industrial
research and development with regard to diseases; active
chemical ingredients for use in the manufacture of
pharmaceuticals. Pharmaceutical and veterinary preparations, Including
pharmaceutical preparations based on antibodies, and bi- and
multispecific antibodies as well as fragments, including
monovalent antibodies, derivatives or conjugates of any of
these for use with regard to diseases. Medical, scientific and biological research, especially
research into antibodies and bi- and multispecific
antibodies or fragments, including monovalent antibodies,
derivatives or conjugates of any of these and development of
pharmaceutical products based on antibodies and bi- and
multispecific antibodies or fragments, including monovalent
antibodies, derivatives or conjugates of any of these;
chemical analysis; computer programming, namely programming
of computers for the collection and processing of medical
data in medical scientific research, development and
therapy, including scientific research, development and
therapy with antibodies and bi- and multispecific antibodies
or fragments, including monovalent antibodies, derivatives
or conjugates of any of these. Patent exploitation and licensing of intellectual property
in the field of medicine.
36.
THERAPEUTIC ANTIBODIES BASED ON MUTATED IGG HEXAMERS
The present invention relates to formulation of antibodies. The invention relates in particular to pharmaceutical compositions comprising an antibody molecule of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Chemical, biochemical, biological, and biotechnological preparations, namely, antibodies, and bi- and multispecific antibodies as well as antibody fragments, monovalent antibodies, and derivatives or conjugates of any of these for in vitro and in vivo scientific and industrial research and development with regard to diseases; active chemical ingredients for use in the manufacture of pharmaceuticals Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations based on antibodies, and bi- and multispecific antibodies as well as antibody fragments, monovalent antibodies, and derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases Medical, scientific and biological research, namely, research into antibodies and bi- and multispecific antibodies as well as antibody fragments, monovalent antibodies, and derivatives or conjugates of any of these and development of pharmaceutical products based on antibodies and bi- and multispecific antibodies or fragments, monovalent antibodies, and derivatives or conjugates of any of these; chemical analysis; computer programming, namely, programming of computers for the collection and processing of medical data in medical scientific research, development and therapy, and scientific research, development and therapy with antibodies and bi- and multispecific antibodies as well as antibody fragments, monovalent antibodies, and derivatives or conjugates of any of these [ Legal services in the field of patent exploitation, namely, patent consultation, patent licensing, and providing information about patent rights; licensing of intellectual property in the field of medicine ]
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
[ Chemical, biochemical, biological, and biotechnological preparations, namely, antibodies, bi- and multispecific antibodies as well as antibody fragments, including monovalent antibodies, and derivatives or conjugates of any of these, for in vitro and in vivo scientific and industrial research and development with regard to diseases; Active chemical ingredients for use in the manufacture of pharmaceuticals ] [ Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations based on antibodies, bi- and multispecific antibodies as well as antibody fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases ] Medical, scientific and biological research, especially research into antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these and development of pharmaceutical products based on antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these; chemical analysis; computer programming, namely, programming of computers for the collection and processing of medical data in medical scientific research, development and therapy, including scientific research, development and therapy with antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these [ Legal services in the field of patent exploitation, namely, patent consultation, patent licensing, and providing information about patent rights; licensing of intellectual property in the field of medicine ]
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
(1) Chemical, biochemical, biological, and biotechnological preparations, especially antibodies, and bi- and multispecific antibodies as well as fragments, namely monovalent antibodies, derivatives and conjugates of any of these for in vitro and in vivo scientific industrial research and development with regard to diseases; active chemical ingredients for use in the manufacture of pharmaceuticals.
(2) Pharmaceutical and veterinary preparations, namely pharmaceutical preparations based on antibodies, and bi- and multispecific antibodies as well as fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases. (1) Medical, scientific and biological research, especially research into antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these and development of pharmaceutical products based on antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these; chemical analysis; computer programming, namely programming of computers for the collection and processing of medical data in medical scientific research, development and therapy, including scientific research, development and therapy with antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these.
(2) Patent exploitation and licensing of intellectual property in the field of medicine.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
(1) Chemical, biochemical, biological, and biotechnological preparations, especially antibodies, and bi- and multispecific antibodies as well as fragments, namely Monovalent antibodies, derivatives and conjugates of any of these for in vitro and in vivo scientific industrial research and development with regard to diseases; active chemical ingredients for use in the manufacture of pharmaceuticals.
(2) Pharmaceutical and veterinary preparations, namely pharmaceutical preparations based on antibodies, and bi- and multispecific antibodies as well as fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases. (1) Medical, scientific and biological research, especially research into antibodies and bi- and multispecific antibodies or fragments, namely monovalent antibodies, derivatives and conjugates of any of these and development of pharmaceutical products based on antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these; chemical analysis; computer programming, namely programming of computers for the collection and processing of medical data in medical scientific research, development and therapy, including scientific research, development and therapy with antibodies and bi- and multispecific antibodies or fragments, including monovalent antibodies, derivatives or conjugates of any of these.
(2) Patent exploitation and licensing of intellectual property in the field of medicine
As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
45.
ANTIBODIES AND METHODS OF USE THEREOF IN TREATMENT OF INFECTIOUS DISEASE
The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of infectious diseases using these compositions
Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
A61K 39/00 - Medicinal preparations containing antigens or antibodies
51.
Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Chemical, biochemical, biological, and biotechnological,
preparations, especially antibodies, bi and multispecific
antibodies as well as fragments, including monovalent
antibodies, derivatives of conjugates of any of these for in
vitro and in vivo scientific and industrial research and
development with regard to diseases. Pharmaceutical and veterinary preparations, including
pharmaceutical preparations based on antibodies, bi and
multispecific antibodies as well as fragments, including
monovalent antibodies, derivatives or conjugates of any of
these for use with regard to diseases. Medical, scientific and biological research; especially
research into antibodies, bi and multispecific antibodies or
fragments, including monovalent antibodies, derivatives or
conjugates of any of these and development of pharmaceutical
products based on antibodies, bi and multispecific
antibodies or fragments; including monovalent antibodies;
derivatives or conjugates of any of these; chemical
analysis; computer programming, namely programming of
computers for the collection and processing of medical data
in medical scientific research, development and therapy,
including scientific research; development and therapy with
antibodies, bi and multispecific antibodies or fragments,
including monovalent antibodies, derivatives or conjugates
of any of these. Legal services in the form of patent exploitation and
licensing of intellectual property in the field of medicine.
Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC- response.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC- response.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Chemical, biochemical, biological, and biotechnological, preparations, namely, antibodies, bi- and multispecific antibodies as well as fragments, monovalent antibodies, derivatives of conjugates of any of these for in vitro and in vivo scientific and industrial research and development with regard to diseases Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations based on antibodies, bi and multispecific antibodies as well as fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases Medical, scientific and biological research; [ medical, scientific and biological ] research in [ the field of ] antibodies, bi and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these and development of pharmaceutical products based on antibodies, bi and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these; chemical analysis [ ; computer programming, namely, programming of computers for the collection and processing of medical data in medical scientific research, development and therapy; development of pharmaceuticals containing antibodies, bi and multispecific antibodies or fragments, monovalent antibodies, derivatives or conjugates of any of these ] Legal services in the form of patent exploitation, namely, patent consultation, patent licensing, and providing information about patent rights; licensing of intellectual property in the field of medicine
